Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.18
+0.10 (0.83%)
Dec 20, 2024, 4:00 PM EST - Market closed
Intellia Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for NTLA stock have an average target of 56.63, with a low estimate of 14 and a high estimate of 120. The average target predicts an increase of 364.94% from the current stock price of 12.18.
Analyst Consensus: Buy
* Price targets were last updated on Nov 19, 2024.
Analyst Ratings
The average analyst rating for NTLA stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 4 | 5 | 5 | 5 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 4 | 4 | 4 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 13 | 15 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $90 | Strong Buy | Maintains | $90 | +638.92% | Nov 19, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $80 → $70 | Buy | Maintains | $80 → $70 | +474.71% | Nov 18, 2024 |
| Wedbush | Wedbush | Hold Reiterates $14 | Hold | Reiterates | $14 | +14.94% | Nov 18, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $88 → $91 | Strong Buy | Maintains | $88 → $91 | +647.13% | Nov 18, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $70 → $60 | Buy | Maintains | $70 → $60 | +392.61% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
55.32M
from 36.28M
Increased by 52.50%
Revenue Next Year
55.55M
from 55.32M
Increased by 0.42%
EPS This Year
-5.42
from -5.42
EPS Next Year
-5.60
from -5.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 83.8M | 220.5M | 166.3M | |||
| Avg | 55.3M | 55.6M | 67.0M | |||
| Low | 44.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 131.0% | 298.6% | 199.4% | |||
| Avg | 52.5% | 0.4% | 20.5% | |||
| Low | 21.6% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -5.10 | -4.35 | -3.91 | |||
| Avg | -5.42 | -5.60 | -5.73 | |||
| Low | -5.49 | -6.64 | -8.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.